
Associate Adjunct Professor
M_Surgery
+1 415 502-0134
Publications
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
NPJ breast cancer
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery.
Clinical cancer research : an official journal of the American Association for Cancer Research
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Cell reports. Medicine
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
JAMA network open
Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Radiology. Imaging cancer
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Frontiers in oncology
Development and testing of a polygenic risk score for breast cancer aggressiveness.
NPJ precision oncology
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Breast cancer research and treatment
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Breast cancer research and treatment
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
NPJ breast cancer
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Nature communications
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
JAMA surgery
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Nature communications
Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Annals of oncology : official journal of the European Society for Medical Oncology
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
International journal of cancer
Survivorship after neoadjuvant chemotherapy - Authors' reply.
The Lancet. Oncology
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
The Lancet. Oncology
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Nature communications
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
Nature communications
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ breast cancer
The WISDOM study: a new approach to screening can and should be tested.
Breast cancer research and treatment
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
NPJ breast cancer
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Cell reports
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Annals of oncology : official journal of the European Society for Medical Oncology
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
NPJ breast cancer
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Annals of oncology : official journal of the European Society for Medical Oncology
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
Journal of the National Comprehensive Cancer Network : JNCCN
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
NPJ breast cancer
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
NPJ breast cancer
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Breast cancer research : BCR
Response to Carter et al.
JNCI cancer spectrum
Androgen receptor gene expression in primary breast cancer.
NPJ breast cancer
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nature communications
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Molecular cancer therapeutics
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Nature cell biology
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
A response to "Personalised medicine and population health: breast and ovarian cancer".
Human genetics
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
JNCI cancer spectrum
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
JCO precision oncology
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Journal of the National Cancer Institute
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Cell reports
Discovery of internalizing antibodies to basal breast cancer cells.
Protein engineering, design & selection : PEDS
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
Journal of medical imaging (Bellingham, Wash.)
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
JAMA oncology
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
NPJ breast cancer
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Breast cancer research : BCR
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Breast cancer research and treatment
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Breast cancer research and treatment
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Breast cancer research and treatment
Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Breast cancer research and treatment
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Nature medicine
Adaptive Randomization of Neratinib in Early Breast Cancer.
The New England journal of medicine
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
The New England journal of medicine
DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas.
NPJ breast cancer
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
JAMA oncology
An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.
Cancer research
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Breast cancer research and treatment
FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
Breast cancer research and treatment
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Breast cancer research : BCR
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
Cancer discovery
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
Annals of surgical oncology
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Annals of surgical oncology
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Breast cancer research : BCR
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Breast cancer research and treatment
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Breast cancer research and treatment
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
Breast cancer research and treatment
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Breast cancer research and treatment
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.
Breast cancer research and treatment
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
Breast cancer research : BCR
Ageing, oxidative stress and cancer: paradigms in parallax.
Nature reviews. Cancer
Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
Breast cancer research : BCR
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
Molecular pharmacology
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Breast cancer research : BCR
Novel pathways associated with quinone-induced stress in breast cancer cells.
Drug metabolism reviews
Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
The international journal of biochemistry & cell biology